Immunicum submits application to FDA for INTUVAX
Immunicum, a Swedish biopharmaceutical company developing therapeutic cancer immunotherapies, has submitted [...]
Cabozantinib and lenvatinib recommended for approval by the EMA
Cabozantinib (Cabometyx, Ipsen Pharma) and lenvatinib (Kisplyx, Eisai Europe Ltd) [...]
Sutent (sunitinib) improves disease-free survival in kidney cancer patients at high risk of recurrence following surgery
Pfizer announced this week that the phase III S-TRAC clinical [...]
Nivolumab blocked by NICE for kidney cancer
Disappointing news for kidney cancer patients: the National Institute for [...]
Nephrectomy adds benefit to targeted therapies in metastatic kidney cancer
A recent study in America has shown that cytoreductive nephrectomy [...]
Could asbestos be a risk factor in kidney cancer as well as mesothelioma?
A new case report published by occupational medicine specialists at [...]
Nivolumab plus ipilimumab combo approved by NICE for melanoma
The National Institute for Health and Care Excellence (NICE) has [...]
Follow-up data from phase I/II clinical trial with INTUVAX in kidney cancer shows promise
Follow-up data from a phase I/II clinical trial with INTUVAX [...]
Take home messages from ASCO
The American Society of Clinical Oncology (ASCO) annual meeting is [...]
Researchers discover a mechanism that reverses TKI drug resistance
Researchers from the Breast Cancer Clinical Research Unit at the [...]
